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Abstract 
 
Aim 
With most studies focusing on long-term survival of prostate cancer patients, there remains a 
need to explore short- to medium-term survival. Using competing risks models, we examined 
how socio-demographic, clinical, and area-level factors are related to prostate cancer 
mortality versus mortality from other causes, a crucial distinction for this disease that 
disproportionately affects men older than 60 years. 
 
Methods 
Using administrative data from the Queensland Cancer Registry in Australia and competing 
risks survival models, we estimated sub-hazard ratios and 95% confidence intervals for men 
diagnosed with prostate cancer (International Classification of Diseases C619). Diagnosis 
was between January 2005 and July 2007, with follow-up to December 2011. Models were 
run for all cases as well as stratified by Gleason score.  
 
Results 
7,393 men were diagnosed with prostate cancer between January 2005 and July 2007. 
Cases had a median follow-up of 5 years 3 months. In the multivariate models for all cases, 
remoteness and area-level disadvantage were not significantly associated with prostate 
cancer mortality. However, area-level disadvantage had a significant negative relationship 
with hazard of death from a cause other than prostate cancer within 7 years; compared with 
those living in the most advantaged areas, the likelihood of mortality was higher for those in 
the most disadvantaged (sub-hazard ratio [SHR] 1.39 [95% confidence interval {CI} 1.01, 
1.90], p = 0.041), disadvantaged (SHR 1.51 [95% CI 1.14, 2.00], p = 0.004), middle (SHR 
1.34 [95% CI 1.02, 1.75], p = 0.034), and advantaged areas (SHR 1.44 [95% CI 1.09, 1.89] , 
p = 0.009). Those with Gleason score of 7 and higher had a lower hazard of prostate cancer 
mortality if they were living with a partner (Gleason score of 7 SHR 0.58 [95% CI 0.40, 0.85], 
p = 0.007; Gleason score 8 to 10 SHR 0.73 [95% CI 0.59, 0.91], p = 0.004). In contrast, 
those with lower Gleason scores had a lower hazard of other-cause mortality if they were 
living with a partner (Gleason score 2 to 6 SHR 0.56 [95% CI 0.41, 0.75], p < 0.001; Gleason 
score of 7 SHR 0.68 [95% CI 0.53, 0.87], p = 0.003).  
 
Conclusions 
Recognition of the living arrangements of men diagnosed with prostate cancer should be a 
priority for clinicians and cancer support personnel to ensure that the men without a partner 
have appropriate support networks. Understanding why men living in more disadvantaged 
areas have higher risk of non-prostate cancer causes of death should be a priority. 
 
Key words 
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Introduction 
 
In this era of prostate-specific antigen screening, most men diagnosed with prostate cancer 
and treated with normal standards of care have no excess mortality compared to the general 
population.1 However, 5- and 10-year relative survival estimates for men diagnosed with 
distant stage prostate cancer of 31% and 20%,1 respectively, suggest that there remains a 
subset of men who do face early mortality due to the disease. In addition, with the incidence 
of prostate cancer increasing with age, men diagnosed with prostate cancer also face the 
risk of dying prematurely from other causes.2 
 
While most prostate cancer mortality studies have considered death over the longer term, 
there remains a need for men diagnosed with this condition to appreciate their overall 
mortality risks in the short to medium term. This may also be helpful in providing appropriate 
reassurance or warning to the patient. 
 
Previous studies have shown that mortality among men diagnosed with prostate cancer 
varies according to marital status,3,4 clinical factors,5,6 and where they live.7–14 However, 
there is little information about how these factors differ according to competing causes of 
death. Also, by including both long- and short-term mortality in their outcome, these previous 
studies were not able to directly inform the short-term mortality risks faced by men 
diagnosed with prostate cancer. Based on related literature, we hypothesize that living 
remote from a major city and living in a socioeconomically disadvantaged area will be 
associated with higher risks of both types of mortality. Understanding how remoteness or 
area-level disadvantage are related to competing risks of mortality could shed light onto 
opportunities for clinicians and policy makers to better serve these communities. 
 
Most previous studies that have considered prostate cancer mortality are either based on 
cancer registry information, and so are limited in the scope of variables they can consider, or 
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else are based on clinical cohorts, in which the representativeness of the cohort can be 
limited. By utilizing population-based data from the Queensland Cancer Registry, 
supplemented with information extracted from pathology and clinical records, we have a 
unique opportunity to investigate how a variety of individual-, clinical- and area-level factors 
interact to impact on the short-term mortality outcomes of men diagnosed with prostate 
cancer, and how these associations vary for competing causes of death. 
 
 
Patients and Methods 
 
Study population 
 
Records of all prostate cancer cases (International Classification of Diseases code C619) 
from January 2005 through July 2007 were abstracted from the Queensland Cancer 
Registry, yielding 7 764 cases. Individuals who were not residents of Queensland at the time 
of diagnosis (n = 293) were excluded, as were those who had previously declined to 
participate in research (n = 16). Ethical approval was given by the Queensland University of 
Technology Human Research Ethics Committee and the ethics committees of ten public 
hospitals in Queensland. Access to data from the Queensland Cancer Registry for the 
purposes of this study was approved by Queensland Health. 
 
Explanatory variables 
 
Australian Bureau of Statistics (ABS) area-level disadvantage and remoteness indices were 
linked to each Statistical Local Area. Area-level disadvantage is a summary measure 
representing the average economic and social conditions of people and households within a 
particular geographic region.15 The ABS Index of Relative Socio-Economic Advantage and 
Disadvantage is cut into quintiles at the population level (categories shown in Table 1). The 
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ABS measure of remoteness (see Table 1) also has five levels, although the categories 
Remote and Very remote were combined for this analysis due to small numbers of cases. 
Prostate cancer cases were placed in categories based on their residential address at 
diagnosis. 
 
Demographic and clinical information were obtained from the Queensland Cancer Registry. 
Additional information on Gleason score was extracted manually from pathology forms held 
within the Registry. Gleason score was determined from, in order of priority, radical 
prostatectomy results, transrectal ultrasound biopsy or transurethral resection of the 
prostate. Consistent with previous studies 5,16, Gleason score was categorized as 2 to 6, 7, 
or 8 to 10 for the purposes of analysis. Age at diagnosis categorized as younger than 65 
years, 65 to 74 years, and 75 years and older. Those divorced, never married, separated, or 
widowed at diagnosis, as recorded on the notifications received by the Queensland Cancer 
Registry, were categorized as “living without a partner;” those married or in a de facto 
relationship at diagnosis were combined into the category “living with a partner.” 
 
Vital status as of 31 December 2011 was obtained through routine matching with the 
Australian National Death Index. Cases were categorized as “prostate cancer death” if the 
medical records held by the Queensland Cancer Registry indicated the person had died of 
prostate cancer (ICD code C619); all other deaths were categorized as “other cause.” 
 
 
Analysis 
 
We tabulated the cases by variables of interest for all cases and by Gleason score 
categories. Using Chi-square tests, we compared the Gleason score subgroups for 
statistically significant differences by the variables of interest.  
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We estimated the Kaplan-Meier (KM) five-year survival function by each variable of interest 
using the cohort method. In this analysis, deaths from causes other than prostate cancer 
were censored. We used log-rank test to compare five-year survivor functions for values 
within each variable. 
 
Using Fine and Gray’s method,17 we conducted cause-specific survival analysis with 
competing risks, with censoring at 31 December 2011. Two types of models were estimated: 
(1) prostate cancer mortality with other cause mortality as a competing risk, and (2) other 
cause mortality with prostate cancer mortality as a competing risk. Models were run for all 
cases and separately within categories based on tumor score. Cases with missing values for 
any of the variables were excluded from the analysis. Since the presence of a poorly-
differentiated tumor is a prime determinant of prostate cancer mortality,5 we controlled for 
Gleason score. To enable the use of likelihood ratio tests to assess the significance of 
variables, we used data expansion via the stcrprep command in Stata and then used the 
stcox command to fit the multivariate models. Sensitivity analyses (not shown) demonstrated 
negligible differences in point estimates and standard errors compared to the stcrreg 
command with robust standard errors. 
 
Accounting for competing risks, we estimated the crude cumulative probability function for 
probability of death from prostate cancer, and probability of death from a cause other than 
prostate cancer. All analysis was conducted using Stata 12.1.18 
 
 
Results  
 
There were 7 393 men diagnosed with prostate cancer in Queensland from January 2005 
through July 2007. These cases were followed to the end of 2011. The median follow-up 
period was 5 years 3 months post-diagnosis, ranging from 4 years 5 months to 7 years. 
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Table 1 summarizes the individual and area-level socio-demographic variables and clinical 
variables for all cases and for categories based on Gleason score. The mean age at prostate 
cancer diagnosis was 67 years. The majority of the men were living with a partner. More 
than half lived in major cities and over one-third lived in areas categorized as disadvantaged 
or most disadvantaged. 
 
There were significant differences in individual and area-level characteristics by Gleason 
score. Those with Gleason score 8 to 10 were, on average, older (χ2 = 356.05, df = 2, p < 
0.001), more likely to be without a partner (χ2 = 29.78, df = 1, p < 0.001), and less likely to 
have had a radical prostatectomy (χ2 = 639.89, df = 1, p < 0.001). 
 
Mortality and crude cumulative probability functions 
 
Of the 7 393 men, 1 359 (18.4%) died on or before 31 December 2011. 15% of the cohort 
had failed after 4.5 years. The age-standardized (Australian 2001) non-prostate cancer 
mortality rate among the cancer cohort during the study period was 1 822 cases per 100 000 
person years. This was very similar to the average age-standardized non-prostate cancer 
mortality rate among all males aged 45 years and over in the Queensland population 
between 2006 and 2012 (1 770 cases per 100 000 population). 
 
The crude Kaplan-Meier 5-year survivor functions (Table 1) show that in terms of area-level 
variables, prostate cancer survival was significantly lower for men who lived in more 
disadvantaged areas (log-rank test, χ2 = 13.41, df = 4, p=0.009), however was not 
significantly associated with remoteness (p = 0.264). Socio-demographic factors of younger 
age (χ2 = 388.25, df = 2, p < 0.001) and living with a partner (χ2 = 82.70, df = 1, p < 0.001) 
were significantly associated with higher prostate cancer survival, as were the clinical factors 
of Gleason score 2 to 6 (χ2 = 1010.10, df = 2, p < 0.001), and having had a radical 
prostatectomy (χ2 = 245.40, df = 1, p < 0.001).  
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Figure 1 shows the crude cumulative probability functions of prostate cancer and other 
cause mortality. Into the second year post-diagnosis, the probability of prostate cancer 
mortality was similar to competing cause mortality, and then men with prostate cancer had a 
higher probability of mortality from a competing cause.  
 
Figure 2 illustrates the crude cumulative probability functions of cause-specific mortality by 
Gleason score. Those with Gleason score 7 or greater had significantly higher risk of death 
from prostate cancer than for those with Gleason score 2 to 6.  
 
Short-term prostate cancer mortality 
 
Due to missing data, 6 728 are included in the multivariate analysis. Table 2 displays the 
adjusted sub-hazard ratios (SHR) and 95% confidence intervals (CI) for prostate cancer 
mortality, estimated using competing risks. Area-level variables – remoteness and 
disadvantage - were not significantly associated with prostate cancer mortality in the overall 
model or the model stratified by Gleason score category.  
 
For all cases combined, living with a partner was significantly associated with lower prostate 
cancer mortality (SHR 0.69 [95% CI 0.58, 0.84], p < 0.001) in the multivariate model 
compared to living without a partner. Age was also significantly related to prostate cancer 
mortality, with patients aged 75 years or older having a significantly increased hazard of 
prostate cancer mortality (SHR 1.82 [95% CI 1.43, 2.32], p < 0.001) compared to patients 
diagnosed when younger than 65. Patients aged 65 to 74 did not have an increased risk of 
prostate cancer mortality (p = 0.406) compared to those younger than 65. 
 
When stratified by Gleason score (Table 2), the association of living with a partner was 
significant for those with Gleason score 7 (SHR 0.58 [95% CI 0.40, 0.85], p = 0.007) and 
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Gleason score 8 to 10 (SHR 0.73 [95% CI 0.59, 0.91], p = 0.004) but not for those with 
Gleason score less than 7. The increased prostate cancer mortality for those older than 75 
years was much greater for those with a Gleason score 2 to 6 (SHR 12.97 [95% CI 2.33, 
72.27], p = 0.003) than for those with a score of 7 or greater (SHR 2.46 [95% CI 1.45, 4.18], 
p  = 0.003). 
 
Short-term mortality from other causes 
 
Table 3 presents the SHRs and 95% CIs for other-cause mortality with prostate cancer 
death as the competing risk. For all cases combined, area-level disadvantage emerged as 
an important predictor of mortality. The association between area disadvantage and other 
cause mortality was significant. Compared to those living in the most affluent areas, men 
living in areas categorized as “Most disadvantaged” (SHR 1.39 [95% CI 1.01, 1.90], p = 
0.041), “Disadvantaged” (SHR 1.51 [95% CI 1.14, 2.00], p = 0.004), “Middle SES” (SHR 1.34 
[95% CI 1.02, 1.75], p = 0.034), and “Advantaged” (SHR 1.44 [95% CI 1.09, 1.89], p = 0.009) 
had a significantly higher risk of dying from other causes of death. Remoteness was not 
significantly associated with mortality from other causes. 
 
Living with a partner was associated with lower mortality from other causes (SHR 0.70 [95% 
CI 0.60, 0.82], p < 0.001). Compared to patients younger than 65 years old, those 65 to 74 
years old (SHR 2.21 [95% CI 1.73, 2.84], p < 0.001) and 75 or older (SHR 6.81 [95% CI 
5.29, 8.76], p < 0.001) had a higher hazard of death from other causes. 
 
Table 3 also shows the results of the models for other-cause mortality stratified by Gleason 
score. Area-level disadvantage was not a significant prognostic factor for other-cause 
mortality in the stratified models. Men living with a partner at diagnosis had a lower hazard of 
death for those with Gleason score 2 to 6 (SHR 0.56 [95% CI 0.41, 0.75], p < 0.001) and 
Gleason score 7 (SHR 0.68 [95% CI 0.53, 0.87], p = 0.003). The hazard associated with 
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being 75 or older at diagnosis was greatest for those with Gleason score 2 to 6 (SHR 9.16 
[95% CI 5.90, 14.23], p < 0.001) and less pronounced, although still significant, for other 
Gleason score groups. The decreased hazard of death related to having had a radical 
prostatectomy was evident for those with Gleason score 7 (SHR 0.46 [95% CI 0.31, 0.68], p 
< 0.001) and Gleason score 8 to 10 (SHR 0.45 (95% CI 0.20, 1.00), p = 0.027). 
 
Discussion 
 
Area-level factors 
 
The effect of area-level disadvantage on the short-term mortality of prostate cancer patients 
is well documented worldwide.7–10 What is not as well established is how that effect varies 
depending on the type of mortality. Our use of competing risk models provides unique 
insights in the role of location on short-term mortality faced by men diagnosed with prostate 
cancer.  
 
We found that men who lived in more affluent areas had lower other-cause mortality than 
men in more disadvantaged areas, but there was no difference in prostate cancer mortality. 
The higher other cause mortality among men living in disadvantaged areas is consistent with 
the higher mortality risk due to cardiovascular disease among those living in similar 
areas.19,20 Combined with the knowledge that men living in disadvantaged areas are less 
likely to have had PSA tests, 21–23 our finding is consistent with men living in disadvantaged 
areas having lower awareness and concern about their general health. Our finding that area-
level disadvantage is not related to prostate cancer mortality was unexpected.    
 
In the present study, remoteness was not significantly associated with prostate cancer 
patient mortality, regardless of cause. This was surprising, since the existing literature in 
Australia points to increased prostate cancer mortality by remoteness.11,13,14 However, our 
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study cohort was diagnosed between 2005 and 2007, more recent than the cohorts included 
for the other studies. Future research is needed to better understand whether changes in the 
management of prostate cancer have occurred that may have influenced mortality trends. 
However, our data are not sufficient to provide more than suggestive support to this 
hypothesis.  
 
Individual factors 
 
Our finding that men living with a partner at diagnosis had a reduced risk of short-term 
prostate cancer and other cause mortality is consistent with a growing body of work that 
demonstrates a strong, positive relationship between marriage and survival from prostate 
cancer.3,4,24 The explanations for these associations remain unclear. Being married might 
have a positive influence on nutritional status or other lifestyle choices that affect the 
progression of disease and the ability to tolerate treatment; may have a positive impact on 
the treatment type, quality, and adherence; or could provide the cancer patients with an 
advocate and a support who may have a positive impact on their outcome.25 Based on a 
recent study in the Unites States, this effect is likely to continue and perhaps increase in 
magnitude as time from diagnosis increases. 
 
Using competing risks models and stratifying the cases by Gleason score provided 
additional insight into the protective effect of living with a partner. Those with Gleason score 
of 7 and higher (higher likelihood of proliferation) had a lower hazard of prostate cancer 
mortality if they were living with a partner. Therefore, men with more serious prostate cancer 
disease benefitted from living with a partner, perhaps for the reasons previously mentioned. 
In contrast, those with tumors less likely to proliferate (lower Gleason scores) had a lower 
hazard of other-cause mortality if they were living with a partner. This suggests that living 
with a partner “protects” men from the more probable cause of death: prostate cancer for 
those with serious diagnoses, and other causes for those with less serious prostate cancer. 
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In this analysis, older age increased the hazard of mortality from any cause. Recent work 
has shown that advanced age may result in non-receipt of curative treatment, highlighting an 
age bias in clinical practice.26 While we were able to adjust for receipt of radical 
prostatectomy, we did not have information on other curative treatments, such as external 
beam radiotherapy or brachytherapy. Compared to those younger than 65 years old, there 
was no difference in short-term prostate cancer mortality for those 65 to 74 years old; 
however, this group had a greater probability of mortality from a cause other than prostate 
cancer. These short term patterns are consistent with that reported for long-term mortality 
among men diagnosed with prostate cancer in the United States. 
 
 
Strengths and limitations 
 
Survival analyses of prostate cancer can be biased because of a higher rate of prostate-
specific antigen screening in men of high socioeconomic status21,22 and those in urban 
areas.23 A strength of this study is that we have presented survival analysis stratified by 
Gleason score categories, enabling a more unbiased investigation into personal and area-
level factors on prostate cancer patients’ survival. Given that we only had information on the 
socioeconomic characteristics of areas in which men lived at diagnosis, we were unable to 
investigate the impact of an individual’s socioeconomic status on survival outcomes.  
 
We were also unable to investigate treatment effects. Men with prostate cancer may be 
treated with androgen deprivation therapy, which stabilizes prostate-specific antigen, but is 
associated with metabolic syndrome.27–29 Thus, the use of androgen deprivation therapy may 
increase the probability of prostate cancer specific-mortality shifting to other-cause mortality. 
Subsequent studies could take into account the effect of androgen deprivation therapy on 
cause-specific mortality.  
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The Gleason scoring system was modified by the International Society of Urological 
Pathology at a consensus conference in 2005.30 Given the time period in which these cases 
were diagnosed (2005 – 2007), inconsistencies in Gleason scoring may affect survival 
estimates31 particularly those stratified by Gleason score.  
 
It is acknowledged that cause of death information sourced from death certificate information 
can be inaccurate.32,33 While acknowledging this limitation, the Queensland Cancer Registry 
independently assigns cause of death information using a wide range of information 
including death certificates, autopsy reports and pathology reports, giving increased 
confidence in the registered cause of death.  
 
Conclusion 
 
Our findings highlight the varying mortality risk faced by men diagnosed with prostate cancer 
depending on their specific characteristics, and that men diagnosed with less advanced 
prostate cancer are susceptible to mortality from causes other than prostate cancer. The 
diagnosis of prostate cancer has the potential to be a teachable moment in which men can 
be motivated and encouraged to make lifestyle changes to improve health outcomes.34,35 
The inequalities in non-prostate cancer causes of death in this cohort suggest that specific 
targeting of these groups, especially those living in lower socioeconomic areas should be a 
priority.  
 
Further, the findings highlight a consistent disparity in mortality outcomes for men who are 
living without a partner, even after controlling for clinical factors. Recognition of the living 
arrangements of men diagnosed with prostate cancer should be a priority for clinicians and 
cancer support personnel to ensure that the men without a partner have appropriate support 
networks. Further research is also needed to better understand the factors underlying this 
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association. 
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Table 1: Number (percent) of cases by demographic, clinical, and area-level variables for all cases and by Gleason score, and Kaplan-Meier 
survivor function for prostate cancer mortality by variables of interest 
 All cases Gleason score p-value 
for comparison by 
Gleason score 
Survivor function at 
5 years follow up, 
unadjusted 
p-value for 
comparison by 
survivor function 
 2 to 6  7  8 to 10 
 N = 7 393 n = 1 921 n = 3 717 n = 1 755 
Age at diagnosis     <0.001  <0.001 
     Younger than 65 3 101 (42.0) 43.7% 48.4% 26.5%  0.97  
     65 to 74 2 685 (36.3) 36.2% 36.7% 37.8%  0.93  
     75 and older 1 607 (21.7) 20.1% 16.0% 35.7%  0.81  
Marital statusa     <0.001  <0.001 
     Living with a partner 5 352 (79.4) 79.5% 81.5% 74.9%  0.94  
     Not living with a partner 1 386 (20.6) 20.5% 18.5% 25.1%  0.86  
Gleason score       <0.001 
     2 to 6 1 921 (26.0)     0.99  
     7 3 717 (50.3)     0.97  
     8 to 10 1 755 (23.7)     0.76  
Radical prostatectomy     <0.001  <0.001 
     No 5 155 (69.7) 77.8% 56.8% 88.3%  0.89  
     Yes 2 238 (30.3) 22.2% 43.2% 11.7%  1.00  
Area-level disadvantage    0.001  0.009 
     Most disadvantaged 989 (13.4) 11.3% 13.9% 14.6%  0.91  
     Disadvantaged 1 701 (23.0) 24.3% 21.4% 25.0%  0.92  
     Middle SES 1 960 (26.5) 28.1% 26.4% 25.1%  0.92  
     Advantaged 1 604 (21.7) 22.1% 22.3% 19.9%  0.93  
     Most advantaged 1 139 (15.4) 14.3% 16.0% 15.3%  0.95  
Remoteness     <0.001  0.264 
     Major city 4 070 (55.1) 54.2% 55.6% 54.8%  0.93  
     Inner regional 1 893 (25.6) 23.2% 25.4% 28.7%  0.92  
     Outer regional 1 168 (15.8) 18.8% 15.2% 13.8%  0.92  
     Remote 262 (3.5) 3.8% 3.8% 2.8%  0.92  
a Missing cases = 665 (8.9%) 
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Table 2: Sub-hazard ratio (95% confidence interval) for prostate cancer mortality models with competing risks 
 All cases Gleason score 
  2 to 6 (well-differentiated)  7  8 to 10 (poorly-differentiated) 
 SHR (95% CI) p-value SHR (95% CI) p-value SHR (95% CI) p-value SHR (95% CI) p-value 
Age at diagnosis  <0.001  <0.001  0.001  <0.001 
     Younger than 65 1.00  1.00  1.00  1.00  
     65 to 74 1.11 (0.87, 1.42)  2.21 (0.35, 13.90)  1.48 (0.88, 2.51)  0.97 (0.73, 1.29)  
     75 or older 1.82 (1.43, 2.32)  12.97 (2.33, 72.27)  2.46 (1.45, 4.18)  1.52 (1.16, 1.99)  
Marital status  <0.001  0.154  0.007  0.004 
     Living with a partner 0.69 (0.58, 0.84)  0.52 (0.21, 1.24)  0.58 (0.40, 0.85)  0.73 (0.59, 0.91)  
     Not living with a 
partner 
1.00  1.00  1.00  1.00  
Gleason score  <0.001       
     2 to 6 1.00        
     7 4.09 (2.57, 6.51)        
     8 to 10 20.82 (13.38, 
32.38) 
       
Radical prostatectomy  <0.001  0.543  <0.001  <0.001 
     No 1.00  1.00  1.00  1.00  
     Yes 0.08 (0.04, 0.15)  0.52 (0.05, 6.21)  0.01 (0.00, 0.11)  0.15 (0.08, 0.32)  
Area-level disadvantage  0.216  0.449  0.169  0.605 
     Most disadvantaged 1.35 (0.95, 1.92)  1.55 (0.20, 11.77)  1.44 (0.66, 3.16)  1.32 (0.88, 1.98)  
     Disadvantaged 1.14 (0.83, 1.57)  0.46 (0.06, 3.51)  1.24 (0.59, 2.63)  1.17 (0.82, 1.67)  
     Middle SES 1.34 (1.00, 1.81)  1.18 (0.18, 7.57)  2.04 (1.03, 4.03)  1.22 (0.87, 1.71)  
     Advantaged 1.30 (0.96, 1.75)  0.67 (0.11, 4.13)  1.49 (0.73, 3.07)  1.29 (0.91, 1.81)  
     Most advantaged 1.00  1.00  1.00  1.00  
Remoteness  0.378  0.414  0.322  0.831 
     Major city 1.00  1.00  1.00  1.00  
     Inner regional 1.08 (0.88, 1.34)  1.49 (0.37, 5.98)  0.93 (0.58, 1.48)  1.09 (0.86, 1.39)  
     Outer regional 1.26 (0.96, 1.64)  1.62 (0.48, 5.45)  1.51 (0.91, 2.50)  1.14 (0.82, 1.58)  
     Remote 1.21 (0.72, 2.05)  4.20 (0.65, 27.09)  0.93 (0.33, 2.64)  1.09 (0.56, 2.11)  
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Table 3: Sub-hazard ratio (95% confidence interval) for other cause mortality models with competing risks 
 All cases Gleason score 
  2 to 6 (well-differentiated)  7  8 to 10 (poorly-differentiated) 
 SHR (95% CI) p-value SHR (95% CI) p-value SHR (95% CI) p-
value 
SHR (95% CI) p-value 
Age at diagnosis  <0.001  <0.001  <0.001  <0.001 
     Younger than 65 1.00  1.00  1.00  1.00  
     65 to 74 2.21 (1.73, 2.84)  2.54 (1.61, 3.99)  2.18 (1.50, 3.17)  1.81 (1.11, 2.95)  
     75 or older 6.81 (5.29, 8.76)  9.16 (5.90, 14.23)  6.81 (4.61, 10.06)  4.88 (3.06, 7.78)  
Marital status  <0.001  <0.001  0.003  0.337 
     Living with a partner 0.70 (0.60, 0.82)  0.56 (0.41, 0.75)  0.68 (0.53, 0.87)  0.87 (0.66, 1.15)  
     Not living with a 
partner 
1.00  1.00  1.00  1.00  
Gleason score  0.435       
     2 to 6 1.00        
     7 0.91 (0.76, 1.09)        
     8 to 10 0.89 (0.73, 1.08)        
Radical prostatectomy  <0.001  0.623  <0.001  0.027 
     No 1.00  1.00  1.00  1.00  
     Yes 0.54 (0.41, 0.72)  0.89 (0.54, 1.46)  0.46 (0.31, 0.68)  0.45 (0.20, 1.00)  
Area-level disadvantage  0.043  0.537  0.413  0.064 
     Most disadvantaged 1.39 (1.01, 1.90)  1.02 (0.54, 1.91)  1.38 (0.85, 2.25)  1.79 (1.02, 3.14)  
     Disadvantaged 1.51 (1.14, 2.00)  1.26 (0.75, 2.14)  1.41 (0.91, 2.18)  1.90 (1.13, 3.20)  
     Middle SES 1.34 (1.02, 1.75)  0.90 (0.54, 1.51)  1.50 (0.99, 2.27)  1.65 (1.01, 2.71)  
     Advantaged 1.44 (1.09, 1.89)  1.02 (0.62, 1.69)  1.38 (0.91, 2.11)  2.01 (1.21, 3.35)  
     Most advantaged 1.00  1.00  1.00  1.00  
Remoteness  0.769  0.492  0.239  0.317 
     Major city 1.00  1.00  1.00  1.00  
     Inner regional 1.06 (0.88, 1.27)  1.19 (0.83, 1.71)  1.01 (0.76, 1.34)  1.03 (0.75, 1.42)  
     Outer regional 1.06 (0.85, 1.33)  0.93 (0.62, 1.40)  0.94 (0.66, 1.35)  1.45 (0.98, 2.14)  
     Remote 1.21 (0.82, 1.78)  0.72 (0.31, 1.70)  1.72 (1.02, 2.90)  0.99 (0.44, 2.23)  
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